Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 18th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 18th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 14th 2019

Medical World News: Clinical Updates

Kelly Davio Jaime Rosenberg Samantha DiGrande Laura Joszt, MA

February 14th 2019

Moving Toward the "Tipping Point" for Transformation in Cancer Care

Mary Caffrey

Andrew Pecora, MD, FACP, CPE, recently visited Evidence-Based OncologyTM to discuss the progress of COTA’s, a company created in 2011 to develop technology that Pecora said is poised to transform cancer care delivery by helping oncologists and other specialists make decisions that will yield the best outcomes in the most cost-effective way, all at the point of care.

February 14th 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

Mary Caffrey

Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.

February 13th 2019

What We're Reading: Pediatric Mental Health Care; Brain Cancer Immunotherapy; Preventing Perinatal Depression

AJMC Staff

Half of children in with treatable mental health disorders in the United States do not get treatment; a small study demonstrated benefit with immunotherapy for glioblastoma; a task force recommends counseling services for new mothers at risk of depression.

February 13th 2019

Despite Being Involved in Cancer Treatment Decisions, PCPs Lack Knowledge, Confidence

Jaime Rosenberg

While one-third of primary care providers (PCPs) reported participating in breast cancer treatment decisions with their patients, a significant amount of them also indicated that they were not comfortable or did not feel that they had the necessary knowledge to participate in the treatment decision-making process.

February 13th 2019

Is Immunotherapy the Future of Glioblastoma Treatment?

Samantha DiGrande

Immunotherapy has seen great success in the treatment of numerous cancers, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. But thus far, despite several attempts, the devastating brain disease glioblastoma has not been among the immunotherapy success stories. In fact, glioblastoma researchers have had few advances in more than a decade.

February 12th 2019

Rutgers' Janice Mehnert, MD, on Biomarkers, Being Inclusive in Clinical Trials, and Taking Time to Weigh the Options

Mary Caffrey

From her vantage point at Rutgers Cancer Institute of New Jersey, Janice Mehnert, MD, has had a front-row seat to the immuno-oncology revolution. Mehnert returned to her alma mater in 2007, and since 2014, she has headed Rutgers’ Phase I/ Developmental Therapeutics Program; she is also head of the melanoma research team. Her work on the KEYNOTE-028 trial has produced important results in multiple cancers, including neuroendocrine tumors, thyroid cancer, small cell lung cancer, and, recently, advanced ovarian cancer.

February 12th 2019

Preparing Patients and the Health System for Curative Therapies in the Pipeline

Laura Joszt, MA

Experts at the “Paying for Cures: Ensuring patient access and system sustainability" event discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time.

February 12th 2019

Treatment Advances Averted More Than Half a Million Breast Cancer Deaths Over 3 Decades

Wallace Stephens

Preventive screening and treatment advances have contributed to saving lives for patients with breast cancer. A new study has identified that these changes could be responsible for averting up to 614,500 breast cancer deaths since 1989.

February 10th 2019

Identifying Patient Preferences in MM Treatment Improves Shared Decision Making

Laura Joszt, MA

Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.

February 10th 2019

Podcast: This Week in Managed Care—State of the Union Health Initiatives and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 9th 2019

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

Samantha DiGrande

Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.

February 8th 2019

This Week in Managed Care: February 8, 2019

This week, the top managed care news included President Trump's State of the Union address highlighting healthcare; HHS Secretary Alex Azar taking on drug rebates; and physicians asking Congress to fully implement the HITECH Act.

February 6th 2019

Trump Highlights New Initiatives for Childhood Cancer, HIV in State of the Union

Laura Joszt, MA

During his second State of the Union address, President Trump highlighted past bipartisan accomplishments, such as legislation to confront the opioid crisis, but also outlined future priorities, such as addressing the cost of healthcare and prescription drugs.

February 6th 2019

What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging

AJMC Staff

February 5th 2019

VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans

Laura Joszt, MA

Foundation Medicine announced that it has won a nationwide contract from the Department of Veterans Affairs National Precision Oncology Program. The contract covers all of Foundation Medicine’s tests.

February 5th 2019

Chronic Pain the Top Reason US Patients Seek Medical Marijuana

Allison Inserro

Chronic pain accounted for 62.2% of all patient-reported qualifying conditions under which US patients sought medical marijuana, according to a new paper in Health Affairs.

February 3rd 2019

Podcast: This Week in Managed Care—Congressional Drug Price Hearings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 2nd 2019

Predicting AML Outcomes by Monitoring Minimal Residual Disease

Laura Joszt, MA

Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).

February 2nd 2019

Review Identifies Potential Predictive Biomarkers in Colorectal Cancer

David Bai, PharmD

A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).

February 1st 2019

This Week in Managed Care: February 1, 2019

This week, the top managed care news included House and Senate hearings on the cost of prescription drugs; a study finding patients with diabetes can be safely switched to cheaper insulin; and the first non-chemotherapy combination being approved for the treatment of chronic lymphocytic leukemia.

February 1st 2019

AJMC® in the Press, February 1, 2019

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

January 31st 2019

ASCO Names "Progress in Treating Rare Cancers" as the Advance of the Year

Jaime Rosenberg

Reflecting on a year of breakthrough advancements in the treatment of rare, difficult to treat cancers, the American Society of Clinical Oncology (ASCO) has named “Progress in Treating Rare Cancers” as the Advance of the Year.

January 30th 2019

Discussing the Continuing Decline in Overall Cancer Mortality in the United States

In this podcast, we speak with Rebecca Siegel, MPH, strategic director of surveillance information services in the Intramural Research Department at the American Cancer Society, and the lead author of the annual Cancer Statistics report that estimates the number of new cancer cases and deaths in the United States each year.

January 30th 2019

Mantle Cell Lymphoma (MCL): Treatment Landscape and Access to Care

https://www.pharmacytimes.org/on-demand/mantle-cell-lymphoma-mcl-treatment-landscape-and-access-to-care

January 29th 2019

Care Coordination Is the Top Investment Cancer Programs Can Make, Respondents Say

Laura Joszt, MA

The ninth annual Trending Now in Cancer Care survey identified current and emerging trends for US cancer programs, such as the ongoing threat of drug costs and popular services progams are planning to add in the next 2 years.

January 29th 2019

FDA Approves Ibrutinib Combination as Frontline Treatment for CLL

Jaime Rosenberg

The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).

January 23rd 2019

Managed Care Considerations in Meeting the Complex Needs of Patients with Pancreatic Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-in-meeting-the-complex-needs-of-patients-with-pancreatic-cancer

January 22nd 2019

Treatment Advances Make Supportive Care More Important in Multiple Myeloma

Laura Joszt, MA

As patients with multiple myeloma live longer thanks to advancements in treatments, more attention is being paid to treatment-related toxicities that are becoming more relevant.

January 20th 2019

Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

...

32 33 34 35 36 37 38 39 40

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions